NeoGenomics (MEX:NEO) Current Deferred Revenue: MXN3 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NEO NeoGenomics Inc MEX:NEO
70 GF Score
Price MXN176.40
GF Value MXN179.73
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is NeoGenomics Current Deferred Revenue?

NeoGenomics MEX:NEO 70 Current Deferred Revenue is MXN3 Mil as of Jun. 2026. GuruFocus rates MEX:NEO with a GF Score™ of 70/100 and a GF Value™ of MXN179.73 (Fairly Valued). The stock has 6 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

NeoGenomics's current deferred revenue for the quarter that ended in Jun. 2026 was MXN3 Mil.

NeoGenomics Current Deferred Revenue Related Terms

NeoGenomics Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for NeoGenomics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeoGenomics Current Deferred Revenue Chart

NeoGenomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 106.51 147.33 36.16 8.53 15.32

NeoGenomics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.41 28.91 15.32 10.12 3.39
MEX:NEO
70GF Score
NeoGenomics Inc MEX:NEO
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of MXN3 Mil mean?
NeoGenomics (MEX:NEO) has a Current Deferred Revenue of MXN3 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on NeoGenomics and its competitors.
Is NeoGenomics' Current Deferred Revenue too high?
NeoGenomics' current Current Deferred Revenue is MXN3 Mil. Overall, NeoGenomics has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NeoGenomics' Current Deferred Revenue compare to WGS and CDNA?
NeoGenomics' Current Deferred Revenue of MXN3 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Diagnostics & Research company?
A good Current Deferred Revenue depends on the Medical Diagnostics & Research industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on NeoGenomics and its competitors. NeoGenomics's current Current Deferred Revenue is MXN3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeoGenomics stock overvalued right now?
Based on GuruFocus' analysis, NeoGenomics (MEX:NEO) is currently considered Fairly Valued. The stock's GF Value™ is MXN179.73, compared to a current price of MXN176.40 — trading 1.9% below its estimated fair value. The current Current Deferred Revenue is MXN3 Mil. NeoGenomics' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For NeoGenomics (MEX:NEO), the current Current Deferred Revenue is MXN3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeoGenomics (MEX:NEO) Overvalued in 2026?

Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued. The current stock price of MXN176.40 is trading 1.9% below its estimated GF Value™ of MXN179.73. GuruFocus considers NeoGenomics to be Fairly Valued.

Key valuation signals for MEX:NEO:

  • Current Deferred Revenue: MXN3 Mil
  • GF Value™: MXN179.73 vs. price of MXN176.40 (1.9% below fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the MEX:NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeoGenomics Business Description

Other Exchanges NEO:USANG9:Germany
Address 9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
70GF Score

Get the complete analysis for MEX:NEO

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN176.40
Price
MXN179.73
GF Value